Your session is about to expire
← Back to Search
Study Summary
This trial will test a new Lupus medication to see if it is effective, safe, and well tolerated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Antiphospholipid Syndrome.I tested positive for lupus-related antibodies.I have been diagnosed with severe active lupus nephritis.I do not have active or unstable mental health issues due to lupus.I have been diagnosed with Mixed Connective Tissue Disease, not mainly lupus.My lupus is active, with a score of 6 or more, and affects my joints or skin.I was diagnosed with lupus over 12 weeks ago and meet the SLICC criteria.
- Group 1: Placebo
- Group 2: Afimetoran: Dose 1
- Group 3: Afimetoran: Dose 2
- Group 4: Afimetoran: Dose 3
- Screening: It may take up to 14 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 3 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 3 Months after you stop receiving the treatment.
Frequently Asked Questions
Am I eligible to participate in this medical investigation?
"This medical research requires 344 individuals suffering from Libman-Sacks disease to take part, who should be within the 18 and 70 year old age range."
Does this experiment have vacancies for participants?
"Patient recruitment is still ongoing for this trial, as evidenced by updates to the clinicaltrials.gov listing on November 14th 2022. It was first posted publicly in October 2021."
Are there many centers conducting this exploration in North America?
"This clinical trial is now accepting patients at 50 distinct sites, including Middleburg Heights, Memphis and San Diego. To ensure minimal disruption to your life, please select a clinic that is closest in proximity to you."
What have been the findings in regards to potential risks of BMS-986256 (Oral) for patients?
"The safety of BMS-986256 (Oral) has been assigned a score of 2 based on the available evidence. This is because, although there have been some studies confirming its safety, no research exists yet that demonstrates its efficacy."
Does this investigation offer novel approaches to patient care?
"Since 2020, BMS-986256 (Oral) has been a focus of research. The first investigation into its efficacy was sponsored by Bristol-Myers Squibb and included 24 participants - following this initial assessment the drug received Phase 1 approval. Currently, 2 trials are running in 99 cities across 18 nations around the world."
Are geriatric participants eligible for inclusion in this experiment?
"In order to be a viable candidate for this trial, applicants must fall between the ages of 18 and 70. If underaged or geriatric patients are interested in participating, there are other clinical trials with slightly altered eligibility requirements; 18 studies available to those below 18 years old and 106 studies open for seniors over 65."
Are there any precedential studies that demonstrate the effectiveness of BMS-986256 in an oral form?
"Presently, there are two active medical trials researching the effects of BMS-986256 (Oral). While most of these experiments are being carried out in Osorno and LOS Lagos, a total of 233 clinical centres across the world have been enlisted for this research."
Share this study with friends
Copy Link
Messenger